Project/Area Number |
25460574
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Virology
|
Research Institution | Tokushima Bunri University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | インフルエンザ / ウイルス / RNA ポリメラーゼ / エンドヌクレアーゼ / PA / フラーレン / 漢方 / インフルエンザウイルス / バクチオール / C60 / 漢方薬 / シアロ糖鎖 / RNAポリメラーゼ |
Outline of Final Research Achievements |
To identify potential new anti-influenza compounds, we screened 12 fullerene derivatives using an in vitro influenza A RNA polymerase PA endonuclease inhibition assay. We identified 8 fullerene derivatives that inhibited the endonuclease activity of the PA N-terminal domain or full-length PA protein in vitro. In a cell culture system, we found that several fullerene derivatives inhibit influenza A viral infection and the expression of influenza A nucleoprotein and nonstructural protein 1. These results indicate that fullerene derivatives are possible candidates for the development of novel anti-influenza drugs. Furthermore, the Kampo medicines kakkonto, shosaikoto, saikokeishito, keishito, maobushisaishinto, and maoto, but not chikujountanto, inhibited PA endonuclease activity in a dose-dependent manner. Our results indicate that Kampo medicines are good sources providing a structural lead for optimization of an influenza endonuclease inhibitor.
|